Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Chemotherapy for pancreatic cancer.

Literature DB >> 15215490

Chemotherapy for pancreatic cancer.

Stephen L Morris, Matthew Beasley, Martin Leslie.

Abstract

Entities: Disease

Mesh：

Substances：

Year: 2004 PMID： 15215490 DOI： 10.1056/NEJM200406243502617

Source DB: PubMed Journal: N Engl J Med ISSN： 0028-4793 Impact factor: 91.245

Keyword Cloud
Cited

× No keyword cloud information.

9 in total

1. On statistical reanalysis, the EORTC trial is a positive trial for adjuvant chemoradiation in pancreatic cancer.

Authors: Michael C Garofalo; William F Regine; Ming T Tan
Journal: Ann Surg Date: 2006-08 Impact factor: 12.969

2. NCI-RTOG translational program strategic guidelines for the early-stage development of radiosensitizers.

Authors: Yaacov Richard Lawrence; Bhadrasain Vikram; James J Dignam; Arnab Chakravarti; Mitchell Machtay; Boris Freidlin; Naoko Takebe; Walter J Curran; Soren M Bentzen; Paul Okunieff; C Norman Coleman; Adam P Dicker
Journal: J Natl Cancer Inst Date: 2012-12-10 Impact factor: 13.506

Review 3. Adjuvant chemoradiation for pancreatic cancer: what does the evidence tell us?

Authors: Michael D Chuong; Drexell H Boggs; Kruti N Patel; William F Regine
Journal: J Gastrointest Oncol Date: 2014-06

4. Identifying Clinical Factors Which Predict for Early Failure Patterns Following Resection for Pancreatic Adenocarcinoma in Patients Who Received Adjuvant Chemotherapy Without Chemoradiation.

Authors: Steve Walston; Joseph Salloum; Carmine Grieco; Evan Wuthrick; Dayssy A Diaz; Christian Barney; Andrei Manilchuk; Carl Schmidt; Mary Dillhoff; Timothy M Pawlik; Terence M Williams
Journal: Am J Clin Oncol Date: 2018-12 Impact factor: 2.339

Chemotherapy for pancreatic cancer.

1. On statistical reanalysis, the EORTC trial is a positive trial for adjuvant chemoradiation in pancreatic cancer.

2. NCI-RTOG translational program strategic guidelines for the early-stage development of radiosensitizers.

Review 3. Adjuvant chemoradiation for pancreatic cancer: what does the evidence tell us?

4. Identifying Clinical Factors Which Predict for Early Failure Patterns Following Resection for Pancreatic Adenocarcinoma in Patients Who Received Adjuvant Chemotherapy Without Chemoradiation.

Review 5. Adjuvant therapy in pancreatic cancer: a critical appraisal.

6. Stage-specific survival differences associated with postoperative radiotherapy for gastrointestinal cancers.

7. Optimal adjuvant therapy for resected pancreatic cancer: chemotherapy or chemoradiotherapy?

8. Adjuvant radiotherapy for pancreatic cancer is associated with a survival benefit primarily in stage IIB patients.

9. Enhanced tumor targeting of cRGD peptide-conjugated albumin nanoparticles in the BxPC-3 cell line.